Organization | Blood Center of Wisconsin

Blood Center of Wisconsin Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Milwaukee WI United States (1947)

Organization Overview

First Clinical Trial

2006

NCT00331006

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Blood Center of Wisconsin | BloodCenter of Wisconsin, Milwaukee, WI | BloodCenters of Wisconsin

Active Ingredients

Drugs in Phase 3 Trials (1)

nitric oxide (inomax) (1 trial)

Drugs in Phase 2 Trials (6)

hydroxyurea (hydrea) (1 trial)

montelukast (singulair) (1 trial)

red blood cells (2 trials)

rituximab (rituxan) (1 trial)

s303 red blood cells (1 trial)

sodium ferric gluconate complex (2 trials)

Drugs in Other Trials (4)

antihemophilic factor viii human (Hemofil M) (1 trial)

enoxaparin (lovenox) (1 trial)

regadenoson (lexiscan) (1 trial)

von Willebrand factor (recombinant) (Vonvendi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 2)

Anemia, Sickle Cell (Phase 2)

Hemophilia A (Phase 2)

Inflammation (Phase 3)

Thalassemia (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 10
# of Trial APIs: 11